Menopause news from FiercePharma
News
Wyeth to slash another 1,200 jobs
And the ax is falling again. Wyeth notified employees last Friday than another 1,200 jobs will be slashed from the payroll. That's on top of the Read more...
Jury fines Wyeth $134.5M in hormone suit
A Nevada jury didn't buy Wyeth's defense of its menopause drugs Premarin and Prempro. It awarded $134.5 million in compensation to three women who claimed the drugs caused their breast cancer. And Read more...
Novartis' Reclast gets FDA blessing
Score one for Novartis. Its once-yearly treatment for post-menopausal osteoporosis, Reclast, now has the FDA's blessing. Already approved in the U.S. and E.U. for treatment of Paget's bone disease, Read more...
Get more Menopause coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends